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Elucidation of mutagenic processes shaping cancer genomes is a fundamental problem 
whose solution promises insights into new treatment, diagnostic, and prevention strategies1. 
Single-strand DNA-specific APOBEC cytidine deaminase(s) are major source(s) of 
mutations in several cancer types2-4. Previous indirect evidence implicated APOBEC3B as 
the more likely major mutator deaminase, while APOBEC3A's role is not established5,6. 
Using yeast models enabling controlled generation of long single-strand genomic DNA 
substrates7, we show the mutation signatures of APOBEC3A and APOBEC3B are 
statistically distinguishable. We then apply three complementary approaches to identify 
cancer samples with mutation signatures resembling either APOBEC. Strikingly, 
APOBEC3A-like samples have over ten-fold more APOBEC-signature mutations than 
APOBEC3B-like samples. We propose that APOBEC3A mutagenesis is much stronger 
because APOBEC3A itself is highly proficient at generating DNA breaks8-10, whose repair 
can trigger formation of single-strand hypermutation substrates.
Recently, we and others have shown that some cancers have an abundance of apparently 
simultaneous, closely-spaced mutations, variously referred to as ‘kataegis’11 and ‘mutation 
clusters’12. Many clusters are strand- and nucleotide-coordinated, consisting entirely of 
mutations at cytosines on one DNA strand, most frequently within 5′-TCW-3′ motifs 
(mutated cytosine as capital underlined C; W denotes adenine or thymine)4. These 
characteristics are consistent with the mutagenic properties of several APOBEC cytidine 
deaminases which target 5′-TC-3′ motifs in single-strand DNA (ssDNA)13-17.
Analyses of cancer mutation datasets have implicated APOBEC3B (A3B) as the leading 
candidate5,6, with APOBEC3A (A3A) as another possible mutator4. Numerous recent 
reports have linked high A3B expression to various cancers, reflecting a widely held view 
that A3B is the likely major mutator3,4,9,18-22. On the other hand, there is evidence that A3A 
could be a mutator in cancers8-10,23,24. Consistent with this possibility, breast cancers from 
carriers of a germline A3B deletion allele, fusing the A3A transcript to A3B's 3′ regulatory 
sequences, actually tend to have higher TC-signature mutation loads than cancers from non-
carriers25. Such fusion transcripts are more stable, resulting in higher steady-state levels of 
A3A enzyme26.
A more conclusive way to distinguish between possible sources of mutagenesis in cancers is 
to match mutation signatures extracted from statistical analysis of each cancer with well-
defined signature(s) of candidate mutagen(s)27,28. Thus, we collected large numbers of 
mutations induced by either A3A or A3B, in a yeast reporter strain (deleted for uracil 
glycosylase) that generates chromosomal ssDNA upon temperature shift7. Telomere 
uncapping in the presence of ssDNA-damaging mutagens results in selectable mutation 
clusters inactivating multiple reporter genes7,29. Crucially, resection of the complementary 
strand precludes excision repair and uracils from cytidine deaminations gave rise to C → T 
transitions7. pLogo analysis30 of mutations identified by whole genome sequencing (WGS) 
of yeast revealed almost diametrically opposite motif preferences: A3A favored YTCA, 
while A3B favored RTCA (Y = pyrimidine, R = purine, see Fig. 1a–f and Supplementary 
Table 1). This was corroborated by our fold enrichment methodology12 (see Fig. 1g, 1h). 
Re-analysis of mutation data from Neuberger and colleagues, generated by expressing A3A 
or A3B in a conventional yeast system31, yielded similar results (see Supplementary Fig. 1). 
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The motif preferences of APOBECs in yeast should be suitable models for the enzymes’ 
preferences in human cells, since the local sequence contexts flanking cytosines in both 
species’ genomes are quite similar, except for depletion of CpG motifs in human31.
pLogos also showed that mutations at TCA (a component of TCW) were overrepresented for 
both APOBECs, while TCT was underrepresented. Then TCA enrichment in cancers should 
exceed TCW enrichment, if TC mutations were caused by either A3A or A3B. We evaluated 
15 cohorts of recently published cancer WGS samples25,32. Five cancer types2-4 (six 
cohorts, see Fig. 2) had high rates of APOBEC-signature mutagenesis: bladder (BLCA), 
breast (BRCA), head and neck (HNSC), lung adenocarcinoma (LUAD) and squamous cell 
(LUSC). In BLCA, BRCA, and HNSC, high TCA enrichment for APOBEC mutations was 
clearly evident. APOBEC mutagenesis was also detectable in LUAD and LUSC, as shown 
by high TCA enrichment values in C-coordinated mutation clusters, despite high genome-
wide mutation loads from non-APOBEC sources. Low-APOBEC mutagenesis cancer types 
(e.g. multiple myeloma33, where only a small percentage of samples exhibit significant 
APOBEC mutagenesis) are included in Supplementary Table 2.
We next examined the relationship between TCW and TCA enrichments on a per-sample 
basis for the six high-APOBEC cohorts (see Fig. 2). Results for low-APOBEC cohorts are in 
Supplementary Figure 2. We ordered all samples within each cohort by ascending TCW 
enrichment and binned into quartiles (see Fig. 2). As TCW enrichment increased, there was 
a statistically significant trend toward samples with TCA enrichment > TCW enrichment (χ2 
test for trend p-values in Fig. 2). This suggested that A3A, A3B, or both, were mutagenizing 
cancers with high TCW enrichment. Similar results were obtained when analyzing exomes 
from BLCA, BRCA, HNSC, LUAD, LUSC, and cervical cancer (CESC) (see 
Supplementary Fig. 2), bolstering the conclusion that APOBEC(s) preferentially targeting 
TCA were acting in many cancers. APOBEC-signature mutation load in cancer exomes are 
statistically correlated with A3B and A3A transcript abundance4,9. However, this was not a 
reliable metric for distinguishing mutagenicity of specific APOBECs within these cancer 
genomes (see Supplementary Fig. 3), possibly because mRNA abundance in excised tumors 
need not correlate with mRNA (or protein) abundance at time of mutagenesis.
We next sub-categorized TCA-enriched samples into A3A- and A3B-like subsets by 
comparing YTCA enrichment vs. RTCA enrichment (see Fig. 3). Samples with non-random 
ratio of YTCA vs. RTCA mutations (see “Y/RTCA enrichment analysis” in Online 
Methods) were binned by quartile of TCA enrichment. χ2 tests for trend (p-values in Fig. 3) 
indicated significant skewing toward A3A-like signatures as TCA enrichment increased. 
Results for other cohorts are in Supplementary Figure 4. We estimated the minimal number 
of TCA mutations attributable to an APOBEC in each sample (see Fig. 3g and 
Supplementary Table 3), which revealed the overall A3A-like median value (1,480) was 
over 11-fold greater than the A3B-like median (133). Thus, A3A is a much more prolific 
mutator than A3B.
To verify these findings, we compared proportions of mutations at each NTCA in cancers 
vs. each yeast model, using root mean square deviation (RMSD) calculations (see “NTCA 
proportion analysis” in Online Methods), and generated corresponding pLogos for the 
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BRCA ICGC cohort (see Fig. 4). Results for five other high-APOBEC WGS cohorts are in 
Supplementary Figure 5. NTCA and pLogo analyses concurred with Y/RTCA results: lower 
TCA enrichment quartile samples were usually A3B-like (smaller RMSD vs. A3B model), 
transitioning to A3A-like samples (smaller RMSD vs. A3A model) in the upper quartiles.
Recent publications reported that A3B germline deletion carriers are at higher risk for breast 
cancer34,35, and tumors from these patients have higher APOBEC-signature mutagenesis25. 
Thus, we investigated possible relationships between A3B germline copy number variation 
and prevalence of A3A- or A3B-like mutation signatures. By all three analyses, A3B 
deletion samples from the BRCA ICGC cohort were predominantly A3A-like (see Fig. 5a). 
In contrast, A3B wild-type samples showed a roughly equal split between A3A- (Fig. 5b) 
and A3B-like (Fig. 5c) signatures. Fisher's exact tests (p = 0.0024 by Y/RTCA and p = 
0.0277 by NTCA analyses) confirmed significant skewing toward A3A-like signatures 
among A3B deletion samples. Similar results were obtained when the other high-APOBEC 
cohorts were evaluated (see Supplementary Fig. 6).
Our results (summarized in Fig. 6) strongly suggest that, in general, A3A is the predominant 
mutagenic deaminase in cancers. In cancers, APOBEC signatures were clearly detectable 
because abasic sites from uracil excision in ssDNA were not repaired. Instead, they were 
likely bypassed by error-prone translesion DNA polymerases to create mutations (see ref. 36 
and references therein). Our approach relies on the supposition that, with respect to the motif 
preferences of APOBECs, cytosines in yeast ssDNA are suitable models for cytosines in 
ssDNA of human cancers. Since the molecular machinery of DNA transactions are not 
identical between the two species, we do not rule out the possibility that APOBEC motif 
preferences might be at least somewhat different between yeast and human. As sequencing 
technologies mature, it should become feasible to put this question to a rigorous test, by 
analyzing APOBEC motif preferences at thousands of mutated cytosines in human tissue 
culture models and comparing to our results in yeast.
The finding that A3A-signature mutagenesis is more prominent in cancers might seem 
surprising, since A3B mRNA abundance tends to be higher than A3A's in cancer samples 
(see Supplementary Fig. 3). However, A3A is a much more potent inducer of DNA damage, 
likely via strand breakage as demonstrated by staining for γ-H2AX (a marker for double-
strand breaks) and/or comet assay8-10,23. This is also consistent with observations that 
APOBEC-signature mutations and clusters are frequently co-localized with rearrangement 
breakpoints in cancers11,12,37. We propose that A3A-signature mutagenesis is more 
prominent, at least in part, because A3A itself can trigger homology-directed repair 
mediated generation of ssDNA substrates (by end resection38 or break-induced 
replication39) much more readily than A3B can.
As clinical cancer genetics progresses toward genomic analysis of each cancer sample, we 
have recently integrated sample-specific APOBEC-signature mutation analysis into a 
standard platform for analysis of large cancer genome datasets40-42. Analyses to distinguish 
between A3A- vs. A3B-like signatures will be incorporated into future pipeline updates, 
since this might prove important when weighing treatment options, given the substantially 
higher genotoxic and mutagenic potential of A3A. Moreover, early detection of APOBEC-
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signature mutation enrichment, e.g. in cell-free circulating DNA, could have important 
diagnostic or prognostic value, especially for individuals at higher risk, such as A3B 
deletion carriers.
When detected in a tumor sample, a high prevalence of APOBEC mutagenesis might be 
exploited for therapeutic purposes. It has been suggested that hypermutation could enhance 
the effectiveness of immune stimulation therapy to treat cancer, by generating tumor-
specific neoantigens (proteins with new epitopes), that might trigger targeted destruction by 
the immune system43,44. There are two immune therapies for bladder cancers45,46, which 
often have high APOBEC enrichment (see Fig. 2) and A3A-like signatures (see Fig. 3 and 
Supplementary Fig. 5). These clinical observations raise the intriguing possibility that 
hypermutation in bladder cancers (mainly by A3A) could contribute substantially to the 
success of immune therapies. Likewise, other A3A-like, high-APOBEC mutagenesis 
cancers could be promising candidates for similar immune stimulation treatments.
Online Methods
Construction of integrated A3A- and A3B-expressing yeast strains
Human A3A or A3B open read frames (ORFs) with appended 5′ ClaI and 3′ StuI restriction 
sites were codon optimized for expression in yeast, and purchased from DNA 2.0 as inserts 
within the pJ201 vector. Each ORF was released from the vector backbone by ClaI and StuI 
double digestion, and ligated into the multi-cloning site of a tetracycline-regulatable 
pCM252-derived vector47, to create plasmids pSR435 (bearing A3A) and pSR440 (A3B) 
with hph (hygromycin resistance) as the selectable marker instead of TRP1. A fragment of 
each plasmid containing the APOBEC ORF, the tetracycline-regulated promoter, and the 
hph marker, was amplified by PCR with primers (see Supplementary Table 4 for primer 
sequences) to add flanks with homology to either side of the LEU2 gene on Chromosome 
III.
Purified PCR product was transformed48 into a yeast host strain descended from CG37949, 
with the following genotype: MATα his7-2 leu2-3,112 trp1-289 cdc13-1 ung1::NAT. CAN1, 
URA3, and ADE2 were deleted from their native loci and reintroduced into a closely-spaced 
triple reporter gene array near the de novo telomere on the left arm of Chromosome V7. 
Transformants with an APOBEC-hph cassette stably integrated into the LEU2 locus target 
(by homologous recombination) were selected by replica plating onto hygromycin plates, 
and verified by diagnostic replicas on single-colony isolates, followed by DNA sequencing 
of the insert.
Mutagenesis by A3A and A3B in yeast
Yeast were inoculated into 5 mL of YPDA media (1% yeast extract, 2% peptone, 2% 
dextrose, 0.01% adenine sulfate, filter-sterilized) and grown at 23°C for 72 hours. Yeast then 
were diluted ten-fold into 5 mL of fresh YPDA with 20 μg/mL doxycycline hyclate (Sigma-
Aldrich) and shifted to 37°C for 6 hours. Cells then were washed into 5 mL of phosphate-
buffered saline and held at 37°C for 42 hours more. Appropriate dilutions were plated onto 
synthetic complete to verify viability, and onto arginine dropout plates with 60 mg/mL 
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canavanine sulfate and 20 mg/mL adenine sulfate to identify Canr Ade− double mutants, i.e., 
colonies with mutation clusters.
Whole-genome sequencing of yeast
Yeast colonies with mutation clusters were streaked onto YPDA. A single-colony isolate 
from each streak was verified for Can, Ura, Ade, and respiratory competency phenotypes by 
replica plating. Genomic DNA was purified from isolates of interest using a QIAcube robot, 
per manufacturer's instructions (QIAGEN). 100-nucleotide paired-end reads were obtained 
from a HiSeq 2000 sequencer (Illumina). Reads were mapped to the ySR127 reference 
genome and mutations were identified using the fixed ploidy caller in CLC Genomics 
Workbench 7.5 (QIAGEN). To minimize the possibility of analyzing mutations that were 
accumulated during routine passaging and culture growth, only unique mutations were 
included in mutation signature analyses. Illumina reads were uploaded to the NCBI 
Sequence Read Archive.
Cancer and other yeast sequencing data
Cancer genome and exome datasets were obtained from publications25,32 or from the dbGaP 
TCGA controlled access Data Portal. hg19 was the human genome reference for our 
analyses. Cancer mutation catalogues were filtered to remove calls that overlapped with 
entries in dbSNP or the UCSC Genome Browser simpleRepeat track. Data from multiple 
myeloma genomes were from12. Additional yeast data were obtained from31 and re-
analyzed, as described in detail below and previously in4, using the sacCer3 reference 
genome. Only mutations from the ung1Δ background were analyzed, as these were the 
closest equivalents to our yeast data.
APOBEC mRNA abundance and A3B germline copy number data
APOBEC RNAseq data for 5,868 tumor and 834 normal samples across 17 cancer types 
(bladder, breast, cervical, colorectal, glioblastoma multiforme, head and neck, kidney 
chromophobe and renal clear cell, acute myeloid leukemia, lower grade glioma, lung 
adenocarcinoma and squamous cell carcinoma, ovarian, prostate, melanoma, thyroid, and 
uterine corpus endometrial) were downloaded from the Broad GDAC Firehose standard data 
run of Feb. 15, 2014. Segmented copy number (CN) data for 7,191 tumor-normal pairs from 
these same cancer types were downloaded also. 5,526 samples had both RNAseq and CN 
data. These data were available for 17 bladder, 95 breast, 25 head and neck, 44 lung 
adenocarcinoma, and 44 lung squamous cell genomic samples (225 total), which allowed 
mRNA abundance vs. TCA minimal mutation load correlation, and mutation signature vs. 
A3B CN, analyses in this study. A3B CN data for the breast cancer ICGC cohort were 
obtained from25.
A3B copy number annotation
Examination of the segmented CN data revealed that most A3B germline deletion events 
were localized between chr22: 39,363,650 and 39,375,350. Some samples had a short 
deletion within, or multiple discontinuous segmentation events overlapping, this region. This 
necessitated binning of the region into twelve 1-kb windows and identification of all 
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segmental copy number variation (CNV) events overlapping any window. Cutoffs for 
classification were determined by examination of the histogram of inferred A3B CN values 
(see Supplementary Fig. 6f): A3B CN ≤ 0.7, homozygous deletion (homo.del); 0.7 < A3B 
CN ≤ 1.69, heterozygous deletion (het.del); 1.69 < A3B CN ≤ 2.29, wild type (WT); and 
A3B CN > 2.29, amplification (amp). 7,061 samples each had a unique segmental CNV. 
Among the remaining 130 samples that had more than one segmental CNV, classification 
was based on the segmental CN farthest removed from the wild-type value of 2. CN call 
totals were: 99 homo.del (1.38%), 998 het.del (13.88%), 5699 WT (79.25%), and 395 amp 
(5.49%).
Mutation cluster analysis
Mutation cluster analysis was performed as described previously4,12. Mutations spaced ≤ 10 
bases apart were treated as a single mutagenic event, since low fidelity translesion DNA 
synthesis polymerases often synthesize a short tract 3′ of lesion bypass, and mis-incorporate 
at high frequencies50,51. Groups of closely-spaced mutations were identified, such that any 
pair of adjacent mutations within each group was separated by less than 10 kb. To identify 
clusters that were unlikely to have formed by random distribution of mutations within a 
genome, we computed a p-value for each group. Let x = number of bases spanned by a 
group (from first mutation to last), k = number of mutations in a group, π = number of total 
mutations divided by number of total bases in a genome, and j = an indexing parameter. 
Then by the negative binomial distribution52, the cluster p-value:
π was computed using all mutations (i.e., including those filtered for dbSNP and 
simpleRepeat), as this could only increase the p-values. Each group with p-value ≤ 10−4 was 
considered a bona fide mutation cluster. A recursive approach was applied, i.e., all clusters 
passing p-value filtering were identified, even if such a cluster was a subset within a larger 
group that did not pass the p-value filter. Clusters composed of only mutations that 
originated from cytosines along the same DNA strand were classified as C-coordinated. 
Mutations not found in a cluster were classified as scattered.
Mutation signature analyses
Overall structure of signature analysis involving complementary approaches used to 
identify, statistically evaluate and compare mutation signatures is outlined in Figure 6 and 
detailed in sections below.
Enrichment calculations
For all analyses, substitutions at C:G base pairs were treated as mutations at C. Enrichment 
quantifies how frequently C → G or C → T mutations occur at a specific sequence context 
compared to C → G or C → T mutations at cytosines overall. C → A substitutions were 
excluded because such mutations are rare due to abasic site bypass7,36, and to avoid 
confounding overlap with frequent G → T substitutions in some cancers53. To compute 
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enrichment for mutations at TCA, let MutTCA = number of TCA → TGA or TCA → TTA 
mutations and ConTCA = number of occurrences of TCA (and reverse complement TGA) 
contexts within the set of 41-mers centered on each mutation within a sample. Similarly, let 
MutC = number of C → G or C → T mutations and ConC = number of cytosines or guanines 
within the set of 41-mers centered on each mutation within a sample. Then the enrichment 
for mutations at TCA:
Enrichments for the other contexts TC, TCW, RTCA, YTCA, and each NTCA, were 
calculated analogously.
Identification of samples significantly mutated by APOBEC(s)
Statistical overrepresentation of APOBEC mutagenesis within each sample was evaluated 
by one-sided Fisher's exact test. Taking TCA as an example, the test computed the p-value 
for a comparison between the ratio MutTCA / (MutC - MutTCA) vs. the ratio ConTCA / (ConC 
- ConTCA), based on the prediction that the former ratio exceeds the latter. All samples not 
matching this prediction were assigned p = 1. Benjamini-Hochberg (BH) p-value correction 
for multiple testing54 was applied by the p.adjust() function in the R statistical computing 
package. Samples with these adjusted q-values < 0.05 were considered significant.
Estimating the number of mutations created by APOBEC(s)
A minimal estimate for the number of TCA mutations created by APOBEC(s) was 
computed as:
Since enrichment = 1 implies TCA mutations are neither more nor less frequent (when 
corrected for motif abundance) than mutations at C in general, this minimal estimate reports 
the number of TCA mutations in excess of enrichment = 1. It is only this excess which 
should be attributed to mutagenesis by an APOBEC. Samples with Fisher's exact test q > 
0.05 for enrichment at TCA were assigned a MinTCA = 0.
Y/RTCA enrichment analysis
The χ2 test for goodness of fit was used to identify samples that had a ratio of YTCA to 
RTCA mutations which differed statistically from random, by comparing observed vs. 
expected mutation counts. The expected number of YTCA mutations, given the null 
hypothesis of random mutagenesis, simply scales with fraction of motifs at YTCA:
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The expected number of RTCA mutations was computed analogously. p-values were 
corrected by the BH method, with q-values < 0.05 considered significant. Samples within 
each cohort were filtered first for significant TCA mutagenesis enrichment, then for 
significant difference from random distribution of YTCA vs. RTCA mutations. Samples 
passing only the first filter were plotted in the relevant figures as unfilled, gray-bordered 
circles, while samples passing both filters were plotted in colored circles, and included in χ2 
tests for trend toward A3A-like signatures with increasing TCA enrichment.
NTCA proportion analysis
Similarly, the χ2 test for goodness of fit was used to identify samples that had a proportion 
of observed ATCA:CTCA:GTCA:TTCA mutations which differed statistically from 
random. The expected number of mutations at each NTCA:
p-values from comparing observed vs. expected mutation counts were corrected by the BH 
method, with q-values < 0.05 considered significant. Only samples passing filtering for both 
significant TCA mutagenesis enrichment and non-randomness of NTCA proportion were 
included in root mean square deviation (RMSD, also called root mean square error) 
comparisons. RMSD is used commonly to quantify the similarity between two 
corresponding sets of quantities, e.g. the three-dimensional spatial coordinates of alpha-
carbon atoms in one protein structure vs. another55.
RMSD was used to quantify the difference between the normalized enrichment observed in 
each sample for mutations at each NTCA vs. the corresponding normalized enrichment 
values in each yeast model. Taking ATCA as an example, the normalized enrichment:
Let yNENTCA = normalized enrichment for mutations at NTCA observed in a yeast model. 
Then the RMSD of a cancer sample vs. a yeast model:
Samples with RMSD vs. A3A < RMSD vs. A3B were considered A3A-like, while those 
with RMSD vs. A3B < RMSD vs. A3A were A3B-like.
pLogo analysis
pLogos identify nucleotides statistically over- or underrepresented in a ‘foreground’ set of 
sequences, relative to abundances within a ‘background’ set30. pLogos were generated using 
all C → T substitutions from yeast data and all C → G or C → T substitutions from cancer 
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samples. Each element within the set of foreground sequences comprised the two bases 
immediately 5′ of a mutation, the mutated base itself (always C), and one base immediately 
3′. The corresponding background was the set of 41-mers each centered on a mutation 
included in the foreground. The deaminated C was set to position 0. Nucleotides above the 
horizontal axis were overrepresented, while those below the axis were underrepresented. 
The height of each nucleotide denotes the magnitude of over- or underrepresentation. Red 
lines represent cutoffs for p = 0.05. In rare cases, the number of bases in the background set 
was apparently greater than could be accommodated by the pLogo online tool, so the set of 
C → G or C → T substitutions was analyzed separately from the G → C or G → A set. As 
such pairs of pLogos were always very similar, we reported those generated from C → G or 
C → T substitutions only.
Additional statistical analyses
Additional statistical analyses, including Kolmogorov-Smirnov test, Spearman's correlation, 
χ2 test with Yates correction, and χ2 test for trend, were performed using Graphpad Prism 6 
(Graphpad Software).
Code availability
APOBEC mutagenesis pattern was analyzed similarly to the analysis incorporated into the 
Broad's Institute TCGA GDAC Firehose42. R code is available upon request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Analyses of mutations induced by APOBECs in ung1Δ yeast. pLogos show overrepresented 
nucleotides in a motif above the horizontal axis and underrepresented nucleotides below30. 
The size of each letter indicates magnitude of over- or underrepresentation. Fixed positions 
in each motif are highlighted by a box. n(fg) denotes the number of mutations at C, TC, or 
TCA, while n(bg) denotes the number of contexts at C, TC, or TCA. (a) All C:G → T:A 
substitutions induced by (a) A3A or (b) A3B, with C fixed at position 0, indicating 
overrepresentation of TC. (c) A3A and (d) A3B pLogos with fixed TC, revealing 
overrepresentation of TCA. (e) A3A and (f) A3B pLogos with fixed TCA, revealing near-
diametrically opposite preferences at the –2 nucleotide, two positions 5′ of the deamination 
site. (g and h) Enrichment values for APOBEC-related motifs among genome-wide, 
scattered, clustered, and C-coordinated clustered mutations induced by (g) A3A or (h) A3B. 
Note that the similar enrichment values for the same motif (e.g., TCA) among different 
mutation categories suggest that the APOBECs targeted their cognate motifs with similar 
specificity, whether the ssDNA was clustered and presumably persistent (i.e., at uncapped 
telomeres), or scattered and presumably transient (e.g., transcription intermediates).
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Enrichment for mutations at various target motifs among all genome samples, and sample-
by-sample comparison of genome-wide enrichment at TCA vs. TCW, within six cohorts of 
highly APOBEC-mutated cancer types. (a–f) Enrichment for mutations at TC, TCW, TCA, 
RTCA, and YTCA are shown for (a) BLCA, (b) BRCA, (d) HNSC, (e) LUAD, and (f) 
LUSC cohorts from TCGA, as well as (c) a BRCA cohort from ICGC. High genome-wide 
non-APOBEC mutation loads obscured the presence of APOBEC mutagenesis in the lung 
cancers. Nevertheless, APOBEC signature enrichment values in C-coordinated clusters of 
(e) LUAD and (f) LUSC are similar to those in other cancer types (a–d), confirming that 
examination of such clusters is the most sensitive means to detect APOBEC mutagenesis. 
(g–l) Sample-by-sample comparison of enrichment for mutations at TCA vs. TCW for (g) 
BLCA, (h) BRCA, (i) BRCA ICGC, (j) HNSC, (k) LUAD, and (l) LUSC cohorts. Samples 
are binned by quartile of TCW enrichment. χ2 tests for trend (p-values in each panel) 
confirm that as TCW enrichment increases, there is significant skewing toward samples with 
TCA enrichment > TCW enrichment.
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Y/RTCA analysis and estimated mutation load of highly APOBEC-mutated cohorts. (a–f) 
Only samples significantly enriched for mutations at TCA (q < 0.05) are shown. Samples 
with YTCA mutation to RTCA mutation ratio statistically different from random (q < 0.05) 
are binned by quartile of TCA enrichment and plotted as filled symbols. Samples with 
YTCA > RTCA enrichment are considered A3A-like. Those with RTCA > YTCA 
enrichment are A3B-like. p-values from χ2 test for trend are shown. Samples significantly 
enriched at TCA, but with YTCA vs. RTCA ratio not statistically different from random (q 
> 0.05), are plotted as unfilled, gray-bordered symbols and not included in tests for trend. (g) 
The minimal estimated number of TCA mutations attributable to APOBEC mutagenesis, for 
A3A- (pink) or A3B-like (green) samples in each cohort, and for all six cohorts combined, 
are shown along with medians and Kolmogorov-Smirnov p-values. See Online Methods for 
analytical details.
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Three-way comparison of Y/RTCA, NTCA, and pLogo methodologies for identifying 
samples with A3A- or A3B-like signatures in the BRCA ICGC cohort. Samples are binned 
by quartile of TCA enrichment, with 1st (lowest) quartile in (a), 2nd quartile in (b), 3rd 
quartile in (c), and 4th (highest) quartile in (d). All samples in the figure passed statistical 
filtering for significant TCA-signature enrichment (q < 0.05). Samples in Y/RTCA analysis 
also passed statistical filtering for non-random ratio of YTCA vs. RTCA, by χ2 test for 
goodness of fit. Samples in NTCA analysis passed analogous filtering for non-random 
proportion of four NTCA's. In each RMSD graph (middle panels), samples are arranged by 
increasing TCA enrichment. All three analyses indicated that lower TCA enrichment 
samples predominantly have A3B-like signatures, while high enrichment samples in the 
upper quartiles are all A3A-like. See Online Methods for analytical details.
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Relationship between A3B germline copy number and mutation signatures in the BRCA 
ICGC cohort. Samples passed same filtering criteria as in Figure 4. (a) A3B deletion 
samples (one homozygous, denoted by arrowhead; remainder heterozygous) skew toward 
A3A-like signatures. (b) A3A-like and (c) A3B-like subsets of samples with wild-type (WT) 
A3B copy number.
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Summary of data analyses and conclusions. (a and b) Sets of mutations induced by either (a) 
A3A or (b) A3B in yeast are successively more enriched at TC, TCW, and TCA. (a) For 
A3A, mutations at YTCA are more enriched than mutations at RTCA. (b) In contrast for 
A3B, mutations at RTCA are more enriched than mutations at YTCA. (c) By Y/RTCA 
enrichment analysis, out of 243 cancer genome samples with significant TCA mutagenesis, 
101 (41.6%) are A3A-like and 63 (25.9%) are A3B-like. The remaining 79 (32.5%) are 
indeterminate. (d) By NTCA proportion analysis, 124 cancer samples (51.0%) are A3A-like, 
75 (30.9%) are A3B-like, and 44 (18.1%) are indeterminate. (e) In A3B-like cancer samples, 
background A3B mutagenesis results in low overall TCA enrichment signatures with higher 
RTCA (especially ATCA) enrichment. (f) In A3A-like cancer samples, background A3B 
mutagenesis is dwarfed by A3A mutagenic activity, leading to high TCA enrichment 
signatures with even higher YTCA (especially CTCA) enrichment.
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